Skip to main content
29 Sep | 2022

Positive results of a new drug against Alzheimer's

As indicated by Biogen y Eisai, the results show a 27% slowing of cognitive impairment in patients in the early stages of Alzheimer's disease.

28 Sep | 2022

Demonstrated a greater consumption of cerebral glucose in the early stages of Alzheimer's associated with the activation of astrocytes

In the research, led by the Barcelonaβeta Brain Research Center (BBRC), a research center of the Pasqual Maragall Foundation, 314 people without cognitive alterations from the Alfa Study, which has the support of the ”la Caixa” Foundation, have participated - DESTACAT

21 Sep | 2022

Let's make September 21, World Alzheimer's Day, #adaytoforget

On World Alzheimer's Day, we want to make visible the need to continue allocating resources to erase this date from the calendar.

21 Sep | 2022

Research support, key to Alzheimer's prevention

Thanks to the Alfa study, which has the support of the ”la Caixa” Foundation, much progress has been made in recent years in the identification of the early pathophysiological characteristics of Alzheimer's disease, as well as in the its early detection and in the development of prevention strategies.

14 Sep | 2022

The Pasqual Maragall Foundation presents the research grant program Pasqual Maragall Researchers Programme

The Pasqual Maragall Researchers Program (PMRP) research grant program aims to promote clinical or translational research projects in Alzheimer's or other age-related neurodegenerative diseases.

30 Aug | 2022

A new BBRC study links Alzheimer's biomarkers to symptoms of anxiety and depression during confinement by Covid-19

More than 900 people without cognitive alterations from the Alfa Study, which has the support of the "la Caixa" Foundation, have participated in the research.

11 Aug | 2022

A new study identifies two biomarkers in the blood that better capture early signs of Alzheimer's

The study, which used data from almost 400 participants of the ALFA+ Study, determines that the biomarkers p-tau231 and p-tau217 measured in the blood are suitable for indicating brain changes related to the amyloid protein in people without cognitive symptoms.

22 Jul | 2022

Outstanding participation of the BBRC in the AAIC 2022 congress

Our research center will have a notable presence at the Alzheimer's Association International Conference (AAIC 2022), which will be held between July 31 and August 4 in San Diego.

18 Jul | 2022

A new study shows that alterations in biomarkers are associated with higher volumes of gray matter and an increase in glucose metabolism in the brain in cognitively healthy people

Research helps to better understand the relationship between biomarkers of Alzheimer’s disease and the pathophysiological mechanisms that are altered in their early stages.